Terminated PHASE3 INTERVENTIONAL 2-arm NCT00526643

CAPPA-2: Cisplatin Added to Gemcitabine in Poor Performance Advanced NSCLC Patients (CAPPA-2)

Gemcitabine Versus Cisplatin and Gemcitabine in First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer in Poor Physical Condition (Performance Status 2)

Sponsor: Clinical Trials Promoting Group (APRIC/CTPG)

Conditions Non-Small Cell Lung Cancer

Interventions cisplatin gemcitabine

Updated 7 times since 2017 Last updated: Mar 27, 2017 Started: Nov 30, 2007 Primary completion: Dec 31, 2012 Completion: Dec 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

scarce enrolment and presentation of positive results of similar study in June 2012.

Other Non-Small Cell Lung Cancer trials with similar outcome

Browse all Non-Small Cell Lung Cancer trials

Listed as NCT00526643, this PHASE3 trial focuses on Non-Small Cell Lung Cancer and remains terminated or withdrawn. Sponsored by Clinical Trials Promoting Group (APRIC/CTPG), it has been updated 7 times since 2007, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE3
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE3
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE3

▶ Show 2 earlier versions

Apr 2017 — Jun 2018 [monthly]

Terminated PHASE3

Status: Suspended → Terminated
Jan 2017 — Apr 2017 [monthly]

Suspended PHASE3

First recorded

Nov 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Clinical Trials Promoting Group (APRIC/CTPG)
Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
Gruppo Oncologico Italia Meridionale
Gruppo Oncologico Italiano di Ricerca Clinica(GOIRC)
Gruppo Oncologico del Lazio (GOL)
National Cancer Institute, Naples
Northwest Oncology Cooperative Group(GONO)

Data source: National Cancer Institute, Naples

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Acquaviva delle Fonti, Italy , Bari, Italy , Brindisi, Italy , Catanzaro, Italy , Isernia, Italy , Lecce, Italy , Mantova, Italy , Milan, Italy , Monteforte Irpino, Italy , Napoli, Italy and 5 more locations